Limits...
Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer.

Park YH, Choi IY, Yoon SC, Jang HS, Moon HW, Hong SH, Kim SW, Hwang TK, Lee JY - Prostate Int (2015)

Bottom Line: The rate of PSA decrease was maximal in the first month (median -3.34 ng/mL/mo), which then fell gradually with median values of -1.51, -0.32, -0.28, -0.20, and -0.03 ng/mL/mo for durations of 3, 6, 9, 12, and 24 months after SBRT using CyberKnife, respectively.The median PSA nadir was 0.31 ng/mL after a median 23 months.PSA decline occurred rapidly in the first month, and then the rate of PSA decline fell off steadily over time throughout 2 years after treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.

ABSTRACT

Purpose: To assess prostate-specific antigen (PSA) kinetics and report on the oncologic outcomes for patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT) using CyberKnife.

Methods: We extracted the list and data of 39 patients with clinically localized prostate cancer who had undergone primary SBRT using CyberKnife between January 2008 and December 2012 from the Smart Prostate Cancer database system of Seoul St. Mary's Hospital. Changes in PSA over time, PSA velocity, and PSA nadir were evaluated from the completion of SBRT using CyberKnife. Biochemical recurrence (BCR)-free survival after primary SBRT using CyberKnife was determined using Kaplan-Meier analysis.

Results: The rate of PSA decrease was maximal in the first month (median -3.34 ng/mL/mo), which then fell gradually with median values of -1.51, -0.32, -0.28, -0.20, and -0.03 ng/mL/mo for durations of 3, 6, 9, 12, and 24 months after SBRT using CyberKnife, respectively. The median PSA nadir was 0.31 ng/mL after a median 23 months. Kaplan-Meier analysis calculates an actuarial 5-year BCR-free survival after SBRT using CyberKnife as 80.8%.

Conclusions: PSA decline occurred rapidly in the first month, and then the rate of PSA decline fell off steadily over time throughout 2 years after treatment. Also, SBRT using CyberKnife leads to long-term favorable BCR-free survival in localized prostate cancer.

No MeSH data available.


Related in: MedlinePlus

Biochemical recurrence rate after stereotactic body radiation therapy using CyberKnife according to the (A) NCCN risk group and (B) PSA bounce.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494537&req=5

fig3: Biochemical recurrence rate after stereotactic body radiation therapy using CyberKnife according to the (A) NCCN risk group and (B) PSA bounce.

Mentions: Four BCRs (12.8%) were observed over a median follow-up duration of 42.0 (IQR 18.0–64.0) months. In univariate Kaplan–Meier analysis, the actuarial 5-year BCR-free survival was 80.8% (Fig. 2). Two patients in the intermediate-risk group and two in the high-risk group experienced BCRs. Five-year BCR-free survival was 100% for low-risk, 83.9% for intermediate-risk, and 33.3% for high-risk patients (Fig. 3A, P = 0.033). When categorized by PSA bounce, BCR was not observed in patients with PSA bounce, whereas four BCRs were observed in patients without PSA bounce. Although not reaching statistical significance, the 5-year BCR-free survival was 100% for patients with PSA bounce versus 68.7% for the patients without PSA bounce (Fig. 3B, P = 0.100).


Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer.

Park YH, Choi IY, Yoon SC, Jang HS, Moon HW, Hong SH, Kim SW, Hwang TK, Lee JY - Prostate Int (2015)

Biochemical recurrence rate after stereotactic body radiation therapy using CyberKnife according to the (A) NCCN risk group and (B) PSA bounce.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494537&req=5

fig3: Biochemical recurrence rate after stereotactic body radiation therapy using CyberKnife according to the (A) NCCN risk group and (B) PSA bounce.
Mentions: Four BCRs (12.8%) were observed over a median follow-up duration of 42.0 (IQR 18.0–64.0) months. In univariate Kaplan–Meier analysis, the actuarial 5-year BCR-free survival was 80.8% (Fig. 2). Two patients in the intermediate-risk group and two in the high-risk group experienced BCRs. Five-year BCR-free survival was 100% for low-risk, 83.9% for intermediate-risk, and 33.3% for high-risk patients (Fig. 3A, P = 0.033). When categorized by PSA bounce, BCR was not observed in patients with PSA bounce, whereas four BCRs were observed in patients without PSA bounce. Although not reaching statistical significance, the 5-year BCR-free survival was 100% for patients with PSA bounce versus 68.7% for the patients without PSA bounce (Fig. 3B, P = 0.100).

Bottom Line: The rate of PSA decrease was maximal in the first month (median -3.34 ng/mL/mo), which then fell gradually with median values of -1.51, -0.32, -0.28, -0.20, and -0.03 ng/mL/mo for durations of 3, 6, 9, 12, and 24 months after SBRT using CyberKnife, respectively.The median PSA nadir was 0.31 ng/mL after a median 23 months.PSA decline occurred rapidly in the first month, and then the rate of PSA decline fell off steadily over time throughout 2 years after treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.

ABSTRACT

Purpose: To assess prostate-specific antigen (PSA) kinetics and report on the oncologic outcomes for patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT) using CyberKnife.

Methods: We extracted the list and data of 39 patients with clinically localized prostate cancer who had undergone primary SBRT using CyberKnife between January 2008 and December 2012 from the Smart Prostate Cancer database system of Seoul St. Mary's Hospital. Changes in PSA over time, PSA velocity, and PSA nadir were evaluated from the completion of SBRT using CyberKnife. Biochemical recurrence (BCR)-free survival after primary SBRT using CyberKnife was determined using Kaplan-Meier analysis.

Results: The rate of PSA decrease was maximal in the first month (median -3.34 ng/mL/mo), which then fell gradually with median values of -1.51, -0.32, -0.28, -0.20, and -0.03 ng/mL/mo for durations of 3, 6, 9, 12, and 24 months after SBRT using CyberKnife, respectively. The median PSA nadir was 0.31 ng/mL after a median 23 months. Kaplan-Meier analysis calculates an actuarial 5-year BCR-free survival after SBRT using CyberKnife as 80.8%.

Conclusions: PSA decline occurred rapidly in the first month, and then the rate of PSA decline fell off steadily over time throughout 2 years after treatment. Also, SBRT using CyberKnife leads to long-term favorable BCR-free survival in localized prostate cancer.

No MeSH data available.


Related in: MedlinePlus